PROMISE Score for Malignant Pleural Effusion
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–20
- Intermediate-Low Risk21–30
- Intermediate-High Risk31–40
- High Risk41–80
The PROMISE Score for Malignant Pleural Effusion calculates predicting 3-month mortality in patients with malignant pleural effusion using clinical and biological parameters. Key inputs include previous chemotherapy. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. Routine clinical application promotes standardized evidence-based patient management.
Clinical Guidelines & Evidence
Predicts 3-month mortality in patients with malignant pleural effusion using clinical and biological parameters. This validated prognostic tool combines patient characteristics, performance status, laboratory values, and treatment history to provide accurate risk stratification and guide clinical decision-making for patients with malignant pleural effusion.
Clinical Indication
The PROMISE Score for Malignant Pleural Effusion is indicated for bedside clinical practice to support Predicts 3-month mortality in patients with malignant pleural effusion using clinical and biological parameters. This validated prognostic tool combines patient characteristics, performance status, laboratory values, and treatment history to provide accurate risk stratification and guide clinical decision-making for patients with malignant pleural effusion.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Helps guide treatment decisions including pleurodesis, drainage procedures, and palliative care.
Sum of weighted points from: Previous chemotherapy (0-4), Previous radiotherapy (0-2), Hemoglobin level (0-4), WBC count (0-9), CRP level (0-11), ECOG status (0-7), Cancer type (0-6)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| previous_chemotherapy | string | Yes | History of previous chemotherapy treatment |
| previous_radiotherapy | string | Yes | History of previous radiotherapy treatment |
| hemoglobin | string | Yes | Hemoglobin level in g/dL(g/dL) |
| wbc_count | string | Yes | Serum white blood cell count in 10⁹ cells/L(×10⁹ cells/L) |
| crp | string | Yes | C-reactive protein level in mg/L(mg/L) |
| ecog_status | string | Yes | ECOG Performance Status |
| cancer_type | string | Yes | Primary cancer type |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–20 | Low Risk | 3-month mortality <25% |
| 21–30 | Intermediate-Low Risk | 3-month mortality 25-50% |
| 31–40 | Intermediate-High Risk | 3-month mortality 50-75% |
| 41–80 | High Risk | 3-month mortality >75% |
Evidence-Based References (EBM)
- Psallidas I, Kanellakis NI, Gerry S, Thakur N, Bamber J, Dipper A, et al. Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis. Lancet Oncol. 2018;19(7):930-939. doi: 10.1016/S1470-2045(18)30294-8.DOI: 10.1016/S1470-2045(18)30294-8
- Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69(12):1098-104. doi: 10.1136/thoraxjnl-2014-205285.DOI: 10.1136/thoraxjnl-2014-205285
- Yap E, Anderson B, Nair A, Vaska K, Ferland L, Penney B, et al. The role of LENT and PROMISE scores in predicting survival in malignant pleural effusion. Lung. 2022;200(4):459-465. doi: 10.1007/s00408-022-00547-5.DOI: 10.1007/s00408-022-00547-5
Related calculators
- LENT Prognostic Score for Malignant Pleural Effusion
- PROMISE Score for Malignant Pleural Effusion
- LENT Prognostic Score for Malignant Pleural Effusion
- Khorana Risk Score for Venous Thromboembolism in Cancer Patients
- Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC)